Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
OncoResponse raises $40M Series B to target immunotherapy ‘elite responders’
The company aims to develop therapeutics focused on antibodies found in patients who respond well to cancer immunotherapies and develop treatments for those who do not.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Innovation in ADHD: Is it just more of the same?
The ADHD market is booming, with an 8.5% CAGR and estimated sales of $13.9 billion in 2024. Despite the growth, the pipeline seems stuck, reformulating longer-release versions of two existing stimulant drugs.
Morning Read: Full Baxalta-Shire repercussions, a higher-bar for Aetna and Cigna mergers
Also, learn how consumers are gaming Obamacare, the next moves to get better reimbursement for telemedicine, and meet some impressive new venture partners.
Morning Read: Baxalta-Shire isn’t slowing down, biotech IPOs speed up and about those wearables
Also, Withings unveils a smart thermometer at CES, BIO changes its name, and a new British-backed sugar-measuring smartphone app.
presented by
Startups: Astellas on M&A prowl to boost drug pipeline
Astellas is on the lookout for new, early stage drugs to boost its pipeline - particularly because later-stage assets still have overinflated valuations.
Morning Read: Shire coming back at Baxalta, more reasons to ogle Google in healthcare
Plus, another life science IPO in London, a shifting (and slowing) of Obamacare dollars and much more
Morning Read: Shire made a $30B offer to acquire biopharma company Baxalta, patient readmission costs have added up to $420M
Rare disease specialist Shire has made a $30B offer to acquire biopharma company Baxalta, and patient readmission costs have added up to $420M resulting in penalties against hospitals.
Morning Read: Shire gets late stage eye treatment with $300M deal, FDA warns Hospira’s Symbiq infusion system vulnerable to cyberattack
Shire adds to eye treatment portfolio with biotherapeutic deal and FDA issues safety alert for a Hospira infusion pump over concerns that it is vulnerable to a cyberattack.
presented by
Startups: Shire on the lookout for rare disease acquisitions
Shire will likely continue its pursuit of rare disease acquisitions, as CEO Flemming Ornskov hinted at during its latest earnings call. The Irish pharma giant, known largely for its ADHD pipeline, is now focusing in on a rare disease market.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
presented by
What’s the next big biopharma deal? Here are four contenders…
Life sciences M&A activity – and buzz – has hit a fever pitch in the past few months. As the industry braces itself for biosimilars to hit it big and precision medicine to drive development in targeted therapy, even more acquisitions are on the horizon. BioPharma Dive has compiled a tantalizing list of some potential acquisitions: […]
RiverVest finds success in blowing the dust off old compounds
Niall O’Donnell fancies himself an archaeologist of the pharmaceutical persuasion. His firm, RiverVest Ventures, is scoping out the failed and forgotten drugs of big pharma, building companies to repurpose these benched meds for new indications. The aim is to find drugs that have passed for safety in clinical trials, but may have shown limited efficacy […]
Shire sells skin substitute Dermagraft, takes $650 million hit
LONDON (Reuters) – Pharmaceuticals company Shire has agreed to sell its Dermagraft treatment to U.S. group Organogenesis, taking a $650 million hit on the loss-making bio-engineered skin substitute it bought less than three years ago. Shire had hoped that Dermagraft would be the foundation of a regenerative medicine franchise when its acquired owner Advanced BioHealing […]
Big Pharmas take $17M interest in “molecular Trojan horse” to cross the blood-brain barrier
The closely packed cells that form blood vessels to the brain create a physical barrier that has been one of the pharmaceutical industry’s toughest hurdles in developing drugs for neurological diseases. The blood-brain barrier blocks potentially damaging toxins from the brain, but it also keeps out small- and large-molecule drugs. An approach to getting drugs […]
Shire’s asset acquisition to boost Regenerative Medicine Division
Shire (NASDAQ:SHPGY) has acquired the assets of a therapeutics firm, including a vascular surgery technology undergoing phase 2 clinical trials in a move that stands to bolster its regenerative medicine division. As part of the agreement, Shire will provide Pervasis with an up-front payment, along with milestone payments tied to the drugs meeting clinical development, […]